Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2025-05-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券第二次临时受托管理事务报告
Audit Report / Information Classification · 95% confidence The document is titled as a "Second Temporary Trustee Management Affairs Report (2025)" related to the issuance of convertible bonds by 奥锐特药业股份有限公司. It contains detailed information about the bond issuance, terms, interest rates, conversion prices, redemption clauses, bondholder meetings, and other bond-related management matters. The document is prepared by the trustee (国泰海通证券股份有限公司) as per regulatory requirements and agreements. It is not a full annual report, earnings release, or investor presentation. It is a specific report related to the trustee's management of the bond issuance and ongoing bondholder affairs, which fits the category of an Audit Report / Information (AR) as it relates to regulatory compliance and trustee reporting on bond issuance and management. The document length (8261 characters) and content confirm it is a substantive report, not just an announcement or certification. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2025
2025-05-22 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司2024年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2024 Annual General Meeting (AGM) of 奥锐特药业股份有限公司. It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the voting results for various proposals including the annual report, board and supervisory reports, financial statements, profit distribution, and remuneration plans. The document explicitly states it is a legal opinion on the AGM's procedural and voting legality, not the AGM materials themselves. The document is about the AGM event and its voting results, not the full annual report or financial statements. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (5557 characters) and content confirm it is a detailed voting results announcement rather than a brief report publication announcement or the full annual report.
2025-05-16 Chinese
奥锐特药业股份有限公司2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024年年度股东大会决议公告" which translates to "2024 Annual General Meeting Resolution Announcement." It details the date and location of the AGM, attendance, voting results on various proposals including the annual report, board work report, financial statements, profit distribution, and remuneration plans. It also includes legal witness statements confirming the validity of the meeting and voting process. The document is an official announcement of the resolutions passed at the AGM, not the full annual report or financial statements themselves. The length is 3146 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-16 Chinese
奥锐特药业股份有限公司2024年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2024 年年度股东大会 会议资料" which translates to "2024 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items for the 2024 Annual General Meeting, including proposals related to the 2024 Annual Report, Board of Directors' work report, Supervisory Board's work report, financial statements, profit distribution plan, and remuneration plans for directors and senior management. The document also includes meeting procedures, voting instructions, and other materials typically provided to shareholders for an AGM. The document length is about 15,000 characters, indicating it is a full set of meeting materials rather than a brief announcement or a report publication notice. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting.
2025-05-09 Chinese
奥锐特药业股份有限公司关于债券持有人持有可转债比例变动达到10%的公告
Major Shareholding Notification Classification · 95% confidence The document is an official announcement from 奥锐特药业股份有限公司 regarding changes in the holdings of convertible bonds by bondholders, specifically noting a change exceeding 10%. It includes detailed information about bond issuance, bondholder names, quantities held before and after the change, and percentages of total issuance. The document is titled as an announcement and contains no financial statements or comprehensive financial data. It is a regulatory disclosure about bondholder shareholding changes rather than a financial report or earnings release. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels, including bondholder holdings crossing thresholds.
2025-05-08 Chinese
奥锐特药业股份有限公司关于为全资子公司提供担保进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a guarantee provided by the company to its wholly-owned subsidiary. It details the guarantee amount, the internal decision-making process, the financial status of the subsidiary, and the terms of the guarantee agreement. There is no indication that this is a full financial report, audit report, or earnings release. The document is a formal disclosure about a specific financing-related event (providing a guarantee for a subsidiary's loan). It does not contain comprehensive financial statements or management discussion but focuses on a capital/financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 2371 characters, which is consistent with an announcement rather than a full report.
2025-05-08 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.